Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 44 results
Filters: Author is Ribaudo, Heather J  [Clear All Filters]
Found 44 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

L

Lalama CM, Jennings C, Johnson VA, et al. "Comparison of Three Different FDA-Approved Plasma HIV-1 RNA Assay Platforms Confirms the Virologic Failure Endpoint of 200 Copies per Milliliter Despite Improved Assay Sensitivity." J. Clin. Microbiol.. 2015;53(8):2659-66.
Landovitz RJ, Tran TTien T, Cohn SE, et al. "HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-Naïve Men and Women in the United States." AIDS Behav. 2016.
Lehmann DS, Ribaudo HJ, Daar ES, et al. "Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols." Pharmacogenet. Genomics. 2015;25(2):51-9.
Lennox JL, Landovitz RJ, Ribaudo HJ, et al. "Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial." Ann. Intern. Med.. 2014;161(7):461-71.
Li JZ, Paredes R, Ribaudo HJ, et al. "Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis." JAMA. 2011;305(13):1327-35.
Li JZ, Paredes R, Ribaudo HJ, et al. "Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure." AIDS. 2012;26(2):185-92.
Li JZ, Paredes R, Ribaudo HJ, et al. "Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure." J. Infect. Dis.. 2013;207(6):893-7.

Pages